Order Article Reprints

Wu C-E, Chang C-F, Huang C-Y, Yang C-T, Kuo C-HS, Hsu P-C, Chang JW-C. Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers. 2022; 14(3):674. https://doi.org/10.3390/cancers14030674

Wu, Chiao-En, Ching-Fu Chang, Chen-Yang Huang, Cheng-Ta Yang, Chih-Hsi Scott Kuo, Ping-Chih Hsu, and John Wen-Cheng Chang. 2022. "Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma" Cancers 14, no. 3: 674. https://doi.org/10.3390/cancers14030674

Wu, C.-E., Chang, C.-F., Huang, C.-Y., Yang, C.-T., Kuo, C.-H. S., Hsu, P.-C., & Chang, J. W.-C. (2022). Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma. Cancers, 14(3), 674. https://doi.org/10.3390/cancers14030674